-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 15, it was learned from the food and Drug Administration of Fujian Province that three first-class new drug varieties of three pharmaceutical enterprises in Fujian Province were approved by the State Food and Drug Administration for listing "These are three national heavyweight drug varieties in our province." Fujian According to the relevant person in charge of the provincial food and drug administration, the three first-class new drug varieties approved for listing are guipaizite maleate (API and injection) of Fujian Jinshan biopharmaceutical Co., Ltd., olmesartan ester (API, tablet and capsule) of Fujian Tianquan Pharmaceutical Co., Ltd and omeprazole sodium bicarbonate capsule of Xiamen Encheng Pharmaceutical Co., Ltd 。
Among them, the cardiovascular drugs, guipaizite maleate injection is a calcium channel blocker, which is mainly used to treat cardiovascular and cerebrovascular diseases and peripheral vascular diseases It is a drug originally developed by Dilang pharmaceutical factory in Paris, France The product has been withdrawn from the market in France and some countries in Europe, but it is still in use in Japan and South Korea At present, only the raw materials and injection of cinepazide maleate produced by Beijing Sihuan Pharmaceutical Co., Ltd are sold in the market, with an annual sales volume of about 5 billion yuan Olmesartan axetil is an angiotension II receptor antagonist It is the original drug developed by the first three co Pharmaceutical (Shanghai) Co., Ltd and another new antihypertensive drug after valsartan Since it was listed in China in 2006, its sales volume has increased rapidly, showing strong market vitality Omeprazole sodium bicarbonate capsule belongs to PPI, which is the original research drug of santarus company This variety uses sodium bicarbonate to prevent omeprazole from being degraded by gastric acid It can not only inhibit gastric acid, but also make omeprazole absorbed quickly It is convenient to take After taking the medicine, the blood concentration of human body can reach the peak level quickly, and can effectively control gastric acid.